Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection
Fig 3
bNAb pharmacokinetics in responders.
Fits of model predictions (lines) to data from individual macaques (symbols) of bNAb plasma concentrations for the ten responders in Nishimura et al. [10] obtained by simultaneously fitting our model (Eqs 13–20) to V, A1 and A2 across all macaques. Methods for the fitting procedure. The resulting parameter estimates are in S1 Table. The bNAb serum half-lives averaged across all macaques are 9.0 days (range 2.7–15.8 days) for 3BNC117, and 8.2 days (range 2.5–16.3 days) for 10-1074.